Compare Amphastar Pharmaceuticals Inc (AMPH) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Krispy Kreme Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Krispy Kreme Inc trades at $3.47 (market cap $593.06M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DNUT | |
|---|---|---|
Market Cap | $826.08M | $593.06M |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $4.70 |
52-Week Low | $16.87 | $2.92 |
Enterprise Value | $1.22B | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Krispy Kreme (DNUT) trades at $3.44, up 0.58% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -33.36% net margin and -58.92% ROE, though revenue remains stable near $1.5B. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat forecasts. Analyst sentiment is cautiously optimistic with 50% buy ratings, while technical indicators point to resistance near $4.
Outlook hinges on execution of capital-light expansion and cost controls. Risks include persistent losses and high debt, but potential upside exists if turnaround initiatives boost margins. Investors should weigh analyst optimism against weak cash flow trends and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
